J1 MAC: 84999 Covered

The Oncotype DX® Colon Cancer Assay meets criteria for analytical and clinical validity and clinical utility as a reasonable and necessary Medicare benefit, Palmetto GBA announced after completing a recent assessment.

Effective Sept. 18, 2011 the jurisdiction 1 Part B Medicare administrative contractor (J1-B MAC) says it will reimburse Oncotype DX® Colon Cancer Assay services for patients diagnosed with stage II colon cancer.

The Oncotype DX® Colon Cancer Assay, developed to predict the recurrence risk for patients with stage II colon cancer, is a 12-gene RT-PCR assay performed on paraffin-embedded primary colon tumor tissue.

To report an Oncotype DX® Colon Cancer Assay service provided to a Medicare patient, Palmetto GBA requests providers to submit the following claim information:

• CPT® code 84999 Unlisted chemistry procedure
• Enter ‘Oncotype DX colon’ in the comment/narrative field
• Select the appropriate ICD-9-CM code: 153.0-153.9, 154.0-154.2

Source: Palmetto GBA, “What’s New,” Sept. 29, 2011

• About
• Latest Posts

admin aapc

Latest posts by admin aapc (see all)

• Message From Your Region 6 Representatives | Pam Tienter and Jean Pryor - November 15, 2019
• October | Breast Cancer Awareness Month - September 20, 2019
• US gets the ball rolling on ICD-11 - August 16, 2019